Northfield is currently in the data analysis stage with PolyHeme and expects to report top-line trial data in the fourth quarter of this year, followed by filing its biologic license application with the U.S. Food and Drug Administration in the first half of 2007.
They were among the lucky few who ventured to go to trial, who could afford top-notch defense counsel, and whose trial was presided over by a judge who did not act like part of the prosecution team.